Gerard Dueñas

Gerard Dueñas

Auto-generated profile, based on publicly available information

Gerard Dueñas

Infectious Diseases Department, Hospital Clínic Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal
ACAlberto Cózar-Llistó
Alberto Cózar-Llistó
FMFernanda Meira
Fernanda Meira
GDGerard Dueñas
Gerard Dueñas
PPPedro Puerta-Alcalde
Pedro Puerta-Alcalde
ASAlex Soriano
Alex Soriano
We aimed to describe changes in characteristics and treatment strategies of hospitalised patients with COVID-19 and detail the mortality trend over time. Observational cohort study of all consecutive patients admitted ≥ 48 h to Hospital Clinic of Barcelona for COVID-19 (1 March–30 September 2020). A total of 1645 consecutive patients with COVID-19 were assessed over a 7-month period. Overall mortality (≤30 days) was 9.7% (159 patients), 7.7% in patients hospitalised in regular wards and 16.7 % in patients requiring ICU admission. Overall mortality decreased from 11.6% in the first month to 1.4% in the last month, reflecting a progressive, significant downward trend (p for trend 700 ng/mL (OR 2.3, CI 1.3–4.1), ferritin>489 ng/mL (OR 1.9; CI 1.5–3.2), C-RP>7 mg/dL (OR 2.6; CI 1.5–4.6), and shorter duration from symptom onset to hospital admission (OR 1.11; CI 1.04–1.17) were factors associated with 30-day mortality at hospital admission. Conversely, hospital admission in the last months (OR 0.80; CI 0.65–0.98) was significantly associated with lower mortality. In-hospital mortality has decreased in patients with COVID-19 over the last, few months, even though main patient characteristics remain similar. Several changes made when managing patients may explain this decreasing trend. Our study provides current data on mortality of patients hospitalised with COVID-19 that might be useful in establishing quality of standard of care. EIT Health, European Union´s Horizon 2020 Research and Innovation Programme), EDRD. PPA [CM18/00132], NGP [FI19/00133], and CGV [FIS PI18/01061], have received grants from Ministerio de Sanidad y Consumo, ISCIII.

2 September 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
CGCarolina Garcia-Vidal
Carolina Garcia-Vidal
RARodrigo Alonso
Rodrigo Alonso
ACAna M Camon
Ana M Camon
CCCelia Cardozo
Celia Cardozo
LALaia Albiach
Laia Albiach
ASAlex Soriano
Alex Soriano
Background: The use of remdesivir has demonstrated a significant reduction in the time to recovery in patients with COVID-19. However, the impact on mortality is still controversial. Therefore, it is necessary to evaluate whether there is a specific subgroup of patients in whom an active antiviral therapy also reduces the mortality. Methods: Patients admitted for >48 h in our hospital for a SARS-CoV-2 confirmed or suspected infection from February 2020 to February 2021 were retrospectively analysed. The primary outcome of the study was mortality at 30 days. Univariate and multivariate analyses were performed to identify predictors of mortality. Results: In total, 2607 patients (438 receiving remdesivir and 2169 not) were included with a median (IQR) age of 65 (54–77) years and 58% were male. Four hundred and seventy-six were admitted to the ICU (18.3%) and 264 required invasive mechanical ventilation (10.1%). The global 30 day mortality rate was 10.7%. Pre-admission symptom duration of 4–6 days and ≤3 days was associated with a 1.5- and 2.5-fold increase in the mortality rate, respectively, in comparison with >6 days and treatment with remdesivir was independently associated with a lower mortality rate (OR = 0.382, 95% CI = 0.218–0.671). The analysis showed that the major difference was among patients with shorter pre-admission symptom duration (<6 days). Conclusions: Patients with ≤3 days and 4–6 days from symptom onset to admission are associated with a 2.5- and 1.5-fold higher risk of death, respectively. Remdesivir was associated with 62% reduced odds of death versus standard-of-care and its survival benefit increased with shorter duration of symptoms.

5 February 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
LLLorna Leal
Lorna Leal
MGMaría Del Puerto Bernoy González
María Del Puerto Bernoy González
CCClara Castán
Clara Castán
FMFernanda Meira
Fernanda Meira
GDGerard Dueñas
Gerard Dueñas
SGSILCOR study group
SILCOR study group
In 2020, COVID‐19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open‐label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID‐19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50–72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids ( p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission (2.7; 95% CI, 1.11–6.62), lower risk of requiring mechanical ventilation (0.43; 95% CI, 0.20–0.93) and shorter hospitalization duration ( p = 0.008). Mortality was similar between arms ( p = 0.675). Twenty‐eight patients receiving siltuximab required rescue therapy while only 5 receiving corticosteroids ( p < 0.001). Furthermore, patients receiving corticosteroids had a 53% lower risk of confirmed bacterial or fungal invasive infections (RR 0.47; 95% CI, 0.23–0.95; p = 0.0096). Our results show that initial treatment with corticosteroids was more effective than siltuximab in preventing disease progression, reducing intensive care unit admission, mechanical ventilation, with shorter hospital stays, and fewer infection in COVID‐19 pneumonia. Despite numerous challenges, these findings provide valuable insights into optimizing therapeutic strategies, supporting corticosteroids as a preferred treatment over siltuximab in this setting.